Table 1.
Material | Particle Type | Structure Formed |
Size | Main component | Main Applications | Phase of development |
Ref. |
---|---|---|---|---|---|---|---|
Organic | Liposomes | Colloid vesicular strucutre |
10nm–1000 nm | Lipid | Drug carrier | Phase I, II Clinical Trials |
[63] |
Micelles | Nanosphere; cylinder |
20nm–200 nm | Polymer | Drug carrier | Preclinical | [64] | |
Polymeric nanoparticles |
Nanosphere; nanocapsules |
10nm–1000 nm | Polymer | Drug carrier | Preclinical | [59] | |
Dendrimers | Branch | > 5 nm | poly(amidoamine) | Drug carrier | Preclinical | [62] | |
Inorganic | Gold nanoparticles |
Nanosphere; nanorod; nanoshell |
1nm–100nm | Gold | Drug carrier; photothermal therapy; photoacoustic imaging |
Preclinical | [58,71] |
Iron oxide nanoparticle |
Nanosphere | 10nm–50nm | Iron oxide | Drug carrier; magnetic hyperthermia; MRI |
Phase I, II Clinical Trials |
[57,60] | |
Ferromagnetic discs |
Microdisk | lµm | Iron, nickel | Magnomechanical stimulation |
Preclinical | [61] | |
Ceramic nanoparticle |
Nanosphere | 20nm–100nm | Silica | Drug carrier | Preclinical | [235] | |
Quantum dots | Nanosphere; nanorod |
2–20nm | Cadmium selenide | Fluorescence imaging |
Preclinical | [66] | |
Titanium dioxide nanocrystals |
Sphere | 5 nm | Titanium dioxide | Photodynamic therapy |
Preclinical | [67] | |
Hybrid | More than one type of nanomaterials |
Barge or tanker |
Range depends on materials selected |
Core-metallic and polymeric; corona-single or multiple lipid layers |
Theranostics | Preclinical | [168] |